Glycemic Control and the Brain in Children With Type 1 Diabetes

Nemours Children's Clinic46 enrolled

Overview

The purpose of this study is to determine if improving diabetes control by better controlling blood sugars, will help improve or normalize brain function as compared to routine diabetes care. We will use either the patient's own insulin routine (injections or insulin pumps) or a closed-loop insulin pump (Medtronic 670G). This system uses a continuous glucose monitor (CGM) and an insulin pump to automatically give insulin and may improve control of blood sugars.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Type 1 Diabetes Mellitus

Interventions

Closed Loop (Medtronic 670G)DEVICE

A loaner Medtronic 670G insulin pump, Enlite 3 sensor and GST3C Guardian transmitter will be utilized

Standard CareOTHER

Subjects will continue on their current treatment (insulin pump or injections), with follow up every 3 months.

Eligibility

Sex: ALLMin age: 14 YearsMax age: 17 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Be at least 14 and not yet 18 years old * Must have been diagnosed with T1D prior to 5 years old but after 6 months * For those diagnosed prior to 1 year of age, a positive blood test for an antibody marker will be required * Have been born term or near term (≥34 weeks) and weighed more than≥ 2 kg (4.4lbs) at birth * Be in puberty Exclusion Criteria: * History of intellectual disability, language or learning disability identified before diagnosis of diabetes, or enrollment in a self-contained special education program * ADD/ADHD and/or on stimulant medication * Any known genetic or medical problem that could impair brain development * Abnormalities of the brain/nervous system, visual or hearing problem * History of seizures not associated with fever before diabetes diagnosis * Previous inpatient psychiatric treatment * Unable to have a MRI of the head due to having metal: including metal ear tubes, full set of braces in mouth (retainer is acceptable), other appliances, or vascular clip

Locations (5)

Stanford University

Palo Alto, California, United States

Yale University

New Haven, Connecticut, United States

Nemours Childrens Clinic

Jacksonville, Florida, United States

University of Iowa

Iowa City, Iowa, United States

Outcomes

Primary Outcomes

Changes in Gray Matter Volume in the Brain

Trends in total and regional grey matter volume

Time frame: 6 months

Secondary Outcomes

Changes in Brain Activation (Dorsal Anterior Cingulate, Inferior Frontal Gyrus and/or Parietal Cortex)

Blood Oxygen level diffusion (BOLD) Functional Magnetic Resonance Imaging (fMRI) was measured to assess functional activation occurring during "no-go" relative to "go" trials during a Go/No-Go cognitive task. Parameter estimates for an individual subject are obtained by modeling the subject's BOLD time series at each voxel against the expected BOLD response to a given task. Statistical weights (i.e., parameter estimates of activation strength) are determined based on how closely the observed and expected signals agree for each task condition to create parameter maps over the entire brain. Higher-level parameter estimates are generated via contrasts of the estimates from specific task conditions, which can lead to positive or negative values, depending on the relative activation of the conditions.

Time frame: 6 months

Changes in WASI-II Perceptual Reasoning Index (PRI)

The Wechsler Abbreviated Scale of Intelligence second edition (WASI-II) was used. The WASI-II is composed of four subtests: Block Design, Vocabulary, Matrix Reasoning, and Similarities. The WASI-II used in this study produces a Perceptual Reasoning Index (PRI) score from the Block Design and Matrix Reasoning subtests' age-corrected scaled scores. The index scores are derived from a summation of the comprising scaled scores. The PRI score range is: 50-150. Higher scores mean better outcomes. Change over time in the PRI score is reported in each group.

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.